Retrophin Names Stephen Aselage President, COO - Quick Facts

(RTTNews) - Retrophin, Inc. (RTRX) Wednesday named Stephen Aselage as President and Chief Operations Officer, effective immediately. His role will include managing corporate development activities, including the commercialization of existing products, building out the company's global infrastructure, and exploring new business development opportunities.

Before joining Retrophin in 2012, Aselage was Executive Vice President and Chief Business Officer at BioMarin Pharmaceutical, Inc. Prior to that, he held leadership roles with Sangstat Medical Corp. and Genentech and had served in a variety of sales and sales management positions at companies including Rhone-Poulenc Rorer Pharmaceuticals and Bristol Laboratories.

Commenting on the new appointment, Martin Shkreli, Founder and CEO of Retrophin said: "I have no doubt that the expertise Steve has accumulated during his more than 30-year career in the global pharmaceutical industry will be invaluable as we continue advancing our pipeline of treatments for catastrophic diseases and expanding our commercial product portfolio through strategic transactions."